Over the years, digital technologies have been introduced to improve patients’ adherence to tuberculosis (TB) treatment, but with little research showing how feasible these technologies are.
Research begins into new digital tools to support patients and healthcare workers through tuberculosis treatment
A large global study which aims to determine if digital adherence technologies can provide more patient-friendly approaches to improve tuberculosis (TB) treatment outcomes launches in Ethiopia, Tanzania, South Africa, the Philippines and Ukraine, as part of the ASCENT project.
As the main research phase of the innovative ASCENT project kicks off, we asked the main researchers Jens Levy, Katherine Fielding and Amare Tadesse to elaborate on the study. Why are they so determined to generate scientific evidence on the use of digital adherence technologies for tuberculosis (TB) treatment?
Today is World Tuberculosis Day. This year’s theme, ‘The Clock is Ticking’, tells us that the world is running out of time to act on the commitments to end tuberculosis (TB), especially now that the COVID-19 pandemic is hampering the progress of the ongoing actions.
The run-in phase of the ASCENT project has started, enrolling TB patients on digital adherence technologies in the Philippines and Ethiopia. Ukraine, Tanzania and South Africa will follow soon. With funding and support, Unitaid makes this project possible.
The ASCENT project releases a free Total Cost of Ownership (TCO) Tool, to enable accurate budget forecasting for the implementation and use of Digital Adherence Technologies (DATs) in TB treatment.
The Stop TB Partnership and the ASCENT project are proud to announce the introduction of an easy and efficient way to procure digital adherence technologies.
In July, the ASCENT project organized a virtual meeting for all Research Managers to prepare the study activities that will be conducted in the different ASCENT countries.
The next three and a half years, KNCV Tuberculosis Foundation will lead the innovative ASCENT project.